Press release
Global Adalimumab Biosimilar Market Drivers, Trends and Opportunities Forecasts from 2017 to 2022
Adalimumab Biosimilar Market
Global Adalimumab Biosimilar Market:
WiseGuyReports.com adds “Adalimumab Biosimilar Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database.
WiseGuyReports.Com Publish a New Market Research Report On –
Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1314266-global-adalimumab-biosimilar-market-professional-survey-report-2017
This report studies Adalimumab Biosimilar in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
AET BioTech
Amgen
Boehringer Ingelheim
Coherus Biosciences
Fujifilm Kyowa Kirin Biologics
LG Life Sciences/Mochida Pharmaceutical
Momenta Pharmaceuticals
Oncobiologics
Pfizer
Samsung Bioepsis
Sandoz
Zydus Cadila
By types, the market can be split into
Tablet
Oral Solution
By Application, the market can be split into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India
If you have any special requirements, please let us know and we will offer you the report as you want.
Browse Full Report Details@ https://www.wiseguyreports.com/reports/1314266-global-adalimumab-biosimilar-market-professional-survey-report-2017
Some Major Points from Table of Content:
Table of Contents
Global Adalimumab Biosimilar Market Professional Survey Report 2017
1 Industry Overview of Adalimumab Biosimilar
1.1 Definition and Specifications of Adalimumab Biosimilar
1.1.1 Definition of Adalimumab Biosimilar
1.1.2 Specifications of Adalimumab Biosimilar
1.2 Classification of Adalimumab Biosimilar
1.2.1 Tablet
1.2.2 Oral Solution
1.3 Applications of Adalimumab Biosimilar
1.3.1 Hospital Pharmacy
1.3.2 Retail Pharmacy
1.3.3 Online Pharmacy
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India
2 Manufacturing Cost Structure Analysis of Adalimumab Biosimilar
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Adalimumab Biosimilar
2.3 Manufacturing Process Analysis of Adalimumab Biosimilar
2.4 Industry Chain Structure of Adalimumab Biosimilar
3 Technical Data and Manufacturing Plants Analysis of Adalimumab Biosimilar
3.1 Capacity and Commercial Production Date of Global Adalimumab Biosimilar Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Adalimumab Biosimilar Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Adalimumab Biosimilar Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Adalimumab Biosimilar Major Manufacturers in 2016
…
5 Adalimumab Biosimilar Regional Market Analysis
5.1 North America Adalimumab Biosimilar Market Analysis
5.1.1 North America Adalimumab Biosimilar Market Overview
5.1.2 North America 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.1.4 North America 2016 Adalimumab Biosimilar Market Share Analysis
5.2 China Adalimumab Biosimilar Market Analysis
5.2.1 China Adalimumab Biosimilar Market Overview
5.2.2 China 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.2.3 China 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.2.4 China 2016 Adalimumab Biosimilar Market Share Analysis
5.3 Europe Adalimumab Biosimilar Market Analysis
5.3.1 Europe Adalimumab Biosimilar Market Overview
5.3.2 Europe 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.3.3 Europe 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.3.4 Europe 2016 Adalimumab Biosimilar Market Share Analysis
5.4 Southeast Asia Adalimumab Biosimilar Market Analysis
5.4.1 Southeast Asia Adalimumab Biosimilar Market Overview
5.4.2 Southeast Asia 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5 Adalimumab Biosimilar Regional Market Analysis
5.1 North America Adalimumab Biosimilar Market Analysis
5.1.1 North America Adalimumab Biosimilar Market Overview
5.1.2 North America 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.1.4 North America 2016 Adalimumab Biosimilar Market Share Analysis
5.2 China Adalimumab Biosimilar Market Analysis
5.2.1 China Adalimumab Biosimilar Market Overview
5.2.2 China 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.2.3 China 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.2.4 China 2016 Adalimumab Biosimilar Market Share Analysis
5.3 Europe Adalimumab Biosimilar Market Analysis
5.3.1 Europe Adalimumab Biosimilar Market Overview
5.3.2 Europe 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.3.3 Europe 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.3.4 Europe 2016 Adalimumab Biosimilar Market Share Analysis
5.4 Southeast Asia Adalimumab Biosimilar Market Analysis
5.4.1 Southeast Asia Adalimumab Biosimilar Market Overview
5.4.2 Southeast Asia 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Southeast Asia 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.4.4 Southeast Asia 2016 Adalimumab Biosimilar Market Share Analysis
5.5 Japan Adalimumab Biosimilar Market Analysis
5.5.1 Japan Adalimumab Biosimilar Market Overview
5.5.2 Japan 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Japan 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.5.4 Japan 2016 Adalimumab Biosimilar Market Share Analysis
5.6 India Adalimumab Biosimilar Market Analysis
5.6.1 India Adalimumab Biosimilar Market Overview
5.6.2 India 2012-2017E Adalimumab Biosimilar Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India 2012-2017E Adalimumab Biosimilar Sales Price Analysis
5.6.4 India 2016 Adalimumab Biosimilar Market Share Analysis
6 Global 2012-2017E Adalimumab Biosimilar Segment Market Analysis (by Type)
6.1 Global 2012-2017E Adalimumab Biosimilar Sales by Type
6.2 Different Types of Adalimumab Biosimilar Product Interview Price Analysis
6.3 Different Types of Adalimumab Biosimilar Product Driving Factors Analysis
6.3.1 Tablet of Adalimumab Biosimilar Growth Driving Factor Analysis
6.3.2 Oral Solution of Adalimumab Biosimilar Growth Driving Factor Analysis
Purchase a Copy of This Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1314266
…CONTINUED
More about WiseGuyReports:
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.
WISE GUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune – 411028
Maharashtra, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Adalimumab Biosimilar Market Drivers, Trends and Opportunities Forecasts from 2017 to 2022 here
News-ID: 555212 • Views: …
More Releases from WISE GUY RESEARCH CONSULTANTS PVT. LTD.
CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, T …
Summary:
A new market study, titled “Discover Global CBD Snack Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.
Introduction
“CBD Snack Market”
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and…
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm A …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017”
Chronic lymphocytic leukemia (CLL)
Overview
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections…
Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeu …
WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report “Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018”
Onychomycosis (Tinea Unguium)
Overview
Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and…
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Bet …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018”
Non Alcoholic Fatty Liver Disease (NAFLD)
Overview
Non Alcoholic Fatty Liver Disease (NAFLD) this situation arise when individual have too much fats there your liver. There should be little or no fat in a healthy liver and for most people, carrying a small amount of…
More Releases for Adalimumab
Adalimumab Biosimilar Market Report and Forecast 2024-2032
Global Adalimumab Biosimilar Market Outlook
The adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2024-2032, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.
Adalimumab Biosimilar: Introduction
Adalimumab biosimilars are biologic medical products highly similar to the reference product, Humira, which is used to treat autoimmune diseases. These biosimilars offer comparable efficacy, safety, and quality at a…
Adalimumab Biosimilar Market Size, Share, Trends 2024-2032
The adalimumab biosimilar market is witnessing substantial growth, driven by the rising incidence of rheumatoid arthritis and an increasing geriatric population. Adalimumab, a popular biologic for treating various inflammatory diseases, has seen a surge in biosimilar counterparts due to their cost-effectiveness and expanding applications. The market is expected to grow at a CAGR of about 17.60% from 2024-2032, reflecting significant opportunities for industry players.
Get a Free Sample Report with Table…
Adalimumab Market Insights, Forecast to 2031
"Adalimumab Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Adalimumab market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Adalimumab industry, providing stakeholders with a nuanced perspective on market dynamics.
Furthermore, the…
Adalimumab Market Size, Status & Forecast 2024
Global Adalimumab Market: Overview
Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha (TNFα). When a TNFα binds to a TBFα receptors, it results in an inflammatory response to autoimmune disease. Adalimumab, by binding to a TNFα, lowers the chances of inflammatory response.
View Report @ http://www.transparencymarketresearch.com/adalimumab-market.html
Adalimumab, which…
Adalimumab Market - Forecasts from 2014 to 2020
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which…
Increasing Research and Penetration of Adalimumab Biosimilars Boosts Demand for …
The impending patent expiration has resulted in the sluggish growth rate of the adalimumab market in Latin America. The entry of biosimilars has further aggravated the market’s concerns. Transparency Market Research (TMR) pegs the valuation of the Latin America adalimumab market at US$994.8 mn in 2014. Expanding at a weak CAGR of 0.4% from 2015 to 2023, the market is forecast to reach US$1,186.4 mn by the end of 2023.
Download…
